Research programme: obesity therapies: Wyeth Pharmaceuticals
Latest Information Update: 03 Oct 2011
At a glance
- Originator Haptogen
- Class Antibodies
- Mechanism of Action Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 14 Dec 2005 Preclinical trials in Obesity in Scotland (unspecified route)